
General information concerning the Commission may also be obtained by accessing its Internet server (http://www.usitc.gov). The public record for this investigation may be viewed on the Commission’s electronic docket (EDIS) at http://edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission has received a complaint filed on behalf of Knowles Electronics LLC on December 7, 2011. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain silicon microphone packages and products containing same. The complaint names Analog Devices Inc. of Norwood, MA; Amkor Technology, Inc. of Chandler, AZ and Avnet, Inc. of Phoenix, AZ.

The complainant, proposed respondents, other interested parties, and members of the public are invited to file comments, not to exceed five pages in length, on any public interest issues raised by the complaint. Comments should address whether issuance of an exclusion order and/or a cease and desist order in this investigation would negatively affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers.

In particular, the Commission is interested in comments that:

(i) Explain how the articles potentially subject to the orders are used in the United States;

(ii) identify any public health, safety, or welfare concerns in the United States relating to the potential orders;

(iii) indicate the extent to which like or directly competitive articles are produced in the United States or are otherwise available in the United States, with respect to the articles potentially subject to the orders; and

(iv) indicate whether Complainant, Complainant’s licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to an exclusion order and a cease and desist order within a commercially reasonable time.

Written submissions must be filed no later than by close of business, five business days after the date of publication of this notice in the Federal Register. There will be further opportunities for comment on the public interest after the issuance of any final determination in this investigation.

Persons filing written submissions must file the original document and 12 true copies thereof on or before the deadlines stated above with the Office of the Secretary. Submissions should refer to the docket number (“Docket No. 2864”) in a prominent place on the cover page and/or the first page. The Commission’s rules authorize filing submissions with the Secretary by facsimile or electronic means only to the extent permitted by section 201.8 of the rules (see Handbook for Electronic Filing Procedures, http://www.usitc.gov/secretary/fed_reg_notices/rules/documents/handbook_on ELECTRONIC_cases.pdf). Persons with questions regarding electronic filing should contact the Secretary (202) 205–2000.

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary.

This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.50(a)(4) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10, 210.50(a)(4)).

By order of the Commission.

Issued: December 6, 2011.

James R. Holbein, Secretary to the Commission.

[FR Doc. 2011–32129 Filed 12–14–11; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Pistoia Alliance, Inc

Notice is hereby given that, on November 3, 2011, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Pistoia Alliance, Inc. has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, PerkinElmer, Inc., Waltham, MA; Connected Discovery, London, UNITED KINGDOM; Fulcrum Direct Limited, CBTC, Cardiff, UNITED KINGDOM; The Hyve, Utrecht, THE NETHERLANDS; and Peter Boogaard (Individual), Moorrecht, THE NETHERLANDS, have been added as parties to this venture. Also, Allergan Sales LLC, Irvine, CA; and Cambridgesoft, Waltham, MA, have withdrawn as parties to this venture. In addition, Atlas Platform Corp. has changed its name to GeneStack Limited, Cambridge, UNITED KINGDOM.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and Pistoia Alliance, Inc. intends to file additional written notifications disclosing all changes in membership.

On May 28, 2009, Pistoia Alliance filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on July 15, 2009 (74 FR 34364).

The last notification was filed with the Department on August 17, 2011. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on September 21, 2011 (76 FR 58540).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2011–32108 Filed 12–14–11; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Toyota Motor Corporation and Ford Motor Company Collaboration

Notice is hereby given that, on November 18, 2011, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993,
DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Petroleum Environmental Research Forum

Notice is hereby given that, on November 1, 2011, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Petroleum Environmental Research Forum ("PERF") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Nalco Environmental Solutions, LLC, Sugarland, TX, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and PERF intends to file additional written notifications disclosing all changes in membership. On February 10, 1986, PERF filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on March 14, 1986 (51 FR 8903).

The last notification was filed with the Department on June 2, 2010. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 2, 2010 (75 FR 45156).

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2011–32114 Filed 12–14–11; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA 358E]

Controlled Substances: Proposed Aggregate Production Quotas for 2012

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice.

SUMMARY: This notice establishes the initial 2012 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).

DATES: Effective Date: December 15, 2011.

FOR FURTHER INFORMATION CONTACT: John W. Partridge, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 307–4654.

SUPPLEMENTARY INFORMATION: Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100.

The 2012 aggregate production quotas represent those quantities of Schedule I and II controlled substances that may be produced in the United States in 2012 to provide adequate supplies of each substance for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. 21 U.S.C. 826(a) and 21 CFR 1303.11. These quotas do not include imports of controlled substances for use in industrial processes.

On October 21, 2011, a notice entitled “Controlled Substances: Proposed Aggregate Production Quotas for 2012” was published in the Federal Register (76 FR 65537). That notice proposed the 2012 aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. All interested persons were invited to comment on or object to the proposed aggregate production quotas on or before November 21, 2011.

Sixteen responses (eleven from DEA registered manufacturers, and five from other members of the public) were received within the published comment period, offering comments on a total of 37 Schedule I and II controlled substances. Several comments discussed the national prescription drug abuse epidemic and urged DEA to reduce quotas for prescription painkillers and opioids. Addressing prescription drug abuse requires a multi-faceted approach which includes education, treatment, and enforcement.

The quota system is specifically designed to operate within the statutory framework of the CSA, in conjunction with other controls to enable DEA to monitor the movement of controlled substances and certain chemicals into and through the closed system of distribution to help prevent diversion of such substances into the illicit market. Through the quota system, DEA limits the amount of those substances and chemicals manufactured each year to those quantities that will provide for the estimated medical, scientific, research, and industrial needs, lawful export requirements, and the establishment and maintenance of reserve stocks for the United States. All aspects of the closed system of distribution must work together to reduce or eliminate the diversion of controlled substances.

Other commenters stated that the proposed aggregate production quotas for alfentanil, amphetamine (for sale), codeine (for conversion), codeine (for sale), dihydrocodeine, dihydromorphine, diphenoxylate, hydrocodone (for sale), hydromorphanol, levorphanol, lidocamexafetamine, meperidine, meperidine intermediate A, meperidine intermediate B, meperidine intermediate C, methadone, methadone intermediate, methamphetamine, methylenedihydantoin, morphone (for conversion), morphine (for sale), morphine-N-oxide, nabilone, noroxymorphone (for sale), oxycodone (tincture), oripavine, oxycodone (for conversion), oxycodone (for sale),...